Haptoglobin polymorphism as a prognostic biomarker for peptide vaccine efficacy in cancer patients

• Project/Area Number: 26430148
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor diagnostics
• Research Institution: Kurume University
• Principal Investigator: Shichijo Shigeki 久留米大学, がんワクチンセンター, 准教授 (30080592)
• Co-Investigator(Kenkyū-buntansha): 野口 正典 久留米大学, 先端がん治療研究センター, 教授 (10140691) ; 由谷 茂 久留米大学, がんワクチンセンター, 教授 (20279160) ; 山田 康秀 国立研究開発法人国立がん研究センター, 中央病院, 医長 (80290956) ; 高島 淳生 国立研究開発法人国立がん研究センター, 中央病院, 医員 (20576186)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: ハプトグロビン / サイトカイン / ペプチドワクチン / SNPs / がん / 血漿 / バイオマーカー / がん予後予測 / SNPｓ

Outline of Final Research Achievements

Hp in various types of cancer, in plasma Cytokines measured by Luminex. Above the median for each Hp of prostate cancer, stomach cancer, bladder cancer and urinary tract cancer, and esophageal cancer and less than in survival compared each P < short lifetime highs set at 0.05. On the other hand, showed no significant difference in the biliary tract cancer, lung cancer, breast cancer, brain tumors. In Hp SNPs, overall survival time of A type shorter than that of type G, while A/G type and other difference was recognized.
In addition, cancer suggests that survival differences of species and treatment methods and related cytokines is different. More than cancer suggests that by plasma Hp becomes a prognostic factor.

Research Products

• [Journal Article] Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer (2016)
  • Author(s): Muroya D, Yutani S, Shichijo S, Yamada A, Sakamoto S, Naito M, Okuda K, Morita M, Yamaguchi R, and Itoh K
  • Journal Title: Evidence-Based Complementary and Alternative Medicine Volume: 2016 Issue: 1
  • DOI: 10.1155/2016/5929525
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients (2016)
  • Author(s): Iwasa S, Yamada Y, Heike Y, Shoji H, Honma Y, Komatsu N, Matsueda S, Yamada A, Morita M, Yamaguchi R, Tanaka N, Kawahara A, Kage M, Shichijo S, Sasada T and Itoh K
  • Journal Title: Cancer Sci Volume: 107 Pages: 590-600
  • Peer Reviewed